Anti-Infectives Summit


Published on

Uncovering novel advances for increasing resistance in anti-infective drug development: The global anti-infective market is currently estimated at $66.5 billion, with anti-bacterial agents accounting for more than 50% of sales. Many biotechs and pharmaceutical companies are seeing developments in later stage clinical trials, specifically in anti-bacterial and anti-fungal, both of which are growing in demand. The threat of bacterial resistant strains of infectious diseases continually increases and creates a race to develop an effective resistant drug to combat these strains. The Anti-Infectives Summit will discuss effective lead generation approaches currently being used in anti-bacterial, anti-viral and anti-fungal drug discovery and address which biologics may play a role in anti-infective therapy.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Anti-Infectives Summit

  1. 1. Register by December 4th and Save up to $698 Hear from Leading Experts Including: David J. Payne, PhD Vice President, Antibacterial DPU, Infectious Diseases Center of Excellence Anti-Infectives in Drug Discovery TM GlaxoSmithKline John Finn, PhD Chief Scientific Officer Trius Therapeutics Jeffrey M. Besterman, PhD Executive Vice President, R & D and CSO Summit MethylGene Inc. Malcolm Page, PhD January 25-27, 2010 • Philadelphia, PA Head, Biology Basilea Pharmaceutical International Ltd Adam Friedman, MD Groundbreaking Advances and Key Chief Resident, Department of Medicine, Division of Dermatology Opinions within Anti-Infective Drug Albert Einstein College of Medicine Nkechi Azie, PhD Discovery and Development Senior Medical Director Astellas Pharma US Baoming Jiang, DVM, PhD Gastroenteritis & Respiratory Viruses Lab Branch Centers for Disease Control and Prevention Ly Tam Phan, PhD Senior Director, Medicinal Chemistry Enanta Pharmaceuticals Nachum Kaplan, PhD Vice President, Microbiology Affinium Pharmaceuticals Neil Ryder, PhD Executive Director, Infectious Diseases Novartis Institutes for Biomedical Research Paul Miller, PhD Executive Director, Anti-Bacterials Highlights of this program include: Pfizer Vincent Hernandez • Formulating an appropriate novel anti-infective drug development Senior Scientist pipeline Medicinal Chemistry Anacor Pharmaceuticals • Examining the changing fortunes of antibacterial drug development William Weiss, PhD and commercialization Director of Pre-Clinical Services University Of North Texas Health • Discovering where the next novel antibacterial leads will come from Science Center Scott Mills, PhD • Ascertaining which biologics may play a role in anti-infective therapy Principal Scientist AstraZeneca • Uncovering real challenges and potential solutions for multi-drug resistant gram-negative bacteria Chris Thomson, PhD Director, Licensing & Business Development Astellas Pharma Europe Ltd Neil D. Pearson, PhD Media Director, Medicinal Chemistry, Partners: Antibacterial DPU, Infectious Diseases Center of Excellence in Drug Discovery GlaxoSmithKline John Powers, MD Assistant Professor of Medicine George Washington University School of Medicine and former Lead Medical Officer, Antimicrobial Development, US FDA
  2. 2. Who will you meet at the Summit: Anti-Infectives TM Chief Scientific Officers, Vice Presidents, Directors, Heads, Scientists, Chemists, Research Leaders/Fellows/Advisors and Academics specializing in: • Microbiology • Immunology Infectious Diseases Summit • • Medicinal Chemistry • Clinical Pharmacology January 25-27, 2010 • Philadelphia, PA • Drug Discovery • New Product Development • Scientific Affairs • Licensing • Antibiotics • Infection Discovery • Drug evaluation • Molecular Biotechnology Dear Colleague, • Drug Development • Project Management • Preclinical Development IQPC’s Anti-Infectives Summit aim • Portfolio Management s to provide an opportunity for R&D from pharmaceutical, biotech and leaders • Anti-bacterial/viral/fungal and academia to expand their knowle Microbiological Infections anti-infectives industry as well as dge in the ascertain new opportunities for drug discovery. The need for new agents to com challenges and significant market bat increasing drug-resistance has created both A Special Thanks to our opportunities for pharmaceutical Advisory Board: manufacturers and biotechnology companies. A more integrated app needed from industry, academia roach is • Malcolm Page, PhD, Head, Biology, and government to improve the pipeline as the demand for new anti-infectives Basilea Pharmaceutical International Ltd therapies increases. • Neil Ryder, PhD, Executive Director, You will hear over 16 in-depth sess Infectious Diseases, Novartis Institutes for ions and case study examples inclu Biomedical Research • Targeting superbugs: New Bicycloli ding: des effective against MRSA and VRE • David J. Payne, PhD, Vice President, • A novel regimen for the treatment Antibacterial DPU, Infectious Diseases of TB Center of Excellence in Drug Discovery, • Sustained release of nitric oxide from hybrid nanoparticle platforms GlaxoSmithKline • Emerging market countries and infe Paul Miller, PhD, Executive Director, ctious disease needs • • Multi-Drug Resistant Gram-Nega Anti-Bacterials, Pfizer tive Bacteria - Real challenges and potential solutions • Frederick P. Duncanson, MD, Senior Director, Section Head Infectious Diseases, • Bacterial Fatty Acid Synthesis as targ Neurosciences Product, Creation Unit, Eisai et for AFN-1252, a novel and selective-spectrum Global Clinical Development • ntibiotics for the treatment of stap • Anne Gershon, M.D, Vice President and hylococcal Infection President-Elect, Infectious Diseases • Anti-Infective drug discovery thro Society of America (IDSA) ugh outsourcing and collaboration s • Ronald GM Van Amsterdam, PhD, Additionally, benefit from industry Principal Medical Scientist, Astellas Europe presentations by AstraZeneca, Pfiz GlaxoSmithKline, Trius Therap er, • Arturo Casadevall, MD, PhD, Professor of eutics, Anacor Pharmaceuticals, Microbiology and Immunology and Affinium Pharmaceuticals, Me Novartis, thylGene, Astellas, EnantaPha Medicine, Chair, Department of and many more pharmaceutical, rmaceuticals, biotech and academic experts. This Microbiology and Immunology, Albert promises to be a networking and conference Einstein College of Medicine discussion-filled event leaving you ideas and solutions and to help you with new • Hans-Henrik Kristensen, discover the current novel anti-infe drug development pipelines. ctive Senior Manager, Novozymes A/S We look forward to seeing you in Philadelphia in January! Sponsorship and Exhibition Opportunities ractive P Highly inte .S Sponsorships and exhibits are excellent e pre- opportunities for your company to showcase and informativ its products and services to high-level, targeted rkshops! decision-makers attending Anti-Infectives Simon Curtis conference wo Summit. IQPC and Pharma IQ help companies or details Se e page 5 f Conference Director, Pharma IQ like yours achieve important sales, marketing and branding objectives by setting aside a limited number of event sponsorships and exhibit spaces – all of which are tailored to assist your organization in creating a platform to maximize its exposure at the event. For more information on sponsoring or exhibiting at Anti-Infectives Summit, please contact Mario Matulich at 212-885-2719 or 2 Register online at or call 1-800-882-8684
  3. 3. Main Conference Day 1 Tuesday, January 26, 2010 7:45 Registration and Coffee Novel Therapeutic Approaches and Areas 8:35 Welcome Address and 1:30 Discovering Novel Candidates Affective Against Chairperson’s Opening Remarks Superbugs (Torezolid [TR-701] Case Study) • Discussing effective results for the treatment of severe complicated The Current Anti-Infective Drug Discovery & skin and skin structure infections caused by gram-positive bacteria Development Market Landscape • Displaying positive results especially against drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) 8:45 Opening Keynote: Industry Overview - The • Describing a randomized Phase 2, double-blind, dose-ranging study Current Shape of Anti-Bacterial R&D conducted at eight centers in the United States • Knowing which direction the anti-bacterials market is heading • Examining overall cure rates for severe abscesses, cellulitis, and • Examining the emergence & challenges of novel drug classes wound infections which were 96%, 97%, and 90%, respectively • Evaluating narrow vs broad spectrum • Evaluating a second-generation oral and IV antibacterial drug in the • Bridging the funding gap oxazolidinone class with activity against drug-resistant, gram- • Discussing new strategies and creative partnerships for improving positive bacterial pathogens, including those resistant to linezolid success John Finn, PhD, Chief Scientific Officer, Trius Therapeutics David J. Payne, PhD, Vice President Antibacterial DPU, Infectious Diseases Center of Excellence in Drug Discovery, 2:15 Targeting Superbugs: New Bicyclolides Effective GlaxoSmithKline against MRSA and VRE • Discussing recent advances in macrolide research against MRSA and 9:30 Paradise Lost, Paradise Found? - The Changing VRE • Identifying targeted product profiles Fortunes of Antibacterial Drug Development and • Uncovering the history and discovery of new anti-MRSA macrolides Commercialization • Overcoming bacterial resistance • Changing Environment & Dynamics of Antibacterial Development • In vitro and In vivo activities and Commercialization Ly Tam Phan, PhD, Senior Director Medicinal Chemistry, Enanta • Displaying the steps to become sustainable reinforcement as a Global Pharmaceuticals, Inc. Category Leader (GCL) within the infectious diseases drug discovery arena 3:00 Towards a Novel Regimen for the Treatment of TB: • Current trends – evolving resistance and decreasing investment levels • Understanding current antibacterial market dynamics An Update on PNU-100480 • Examining future pipelines and their implications • Examining the current state of TB therapy and the challenge of increasing medical need Chris Thomson, PhD, Director, Licensing & Business • Displaying updates on ongoing clinical studies with PNU-100480 Development, Astellas Pharma Europe Ltd • Discussing the current status of the global TB drug candidate portfolio 10:15 Networking Break • Evaluating novel strategies for identifying promising new TB regimens Novel Anti-Infective Drug Development Paul Miller, PhD, Executive Director, Anti-Bacterials, Pfizer Approaches 3:45 Networking Break 11:00 Formulating an Appropriate Novel Anti-Infective Drug Development Pipeline 4:30 Sustained Release of Nitric Oxide from Hybrid • Formulating a senior management buy-in for your organization to Nanoparticle Platform: A Novel Therapeutic fight against withdrawing from multidrug-resistant bacteria Strategy for Cutaneous Infections development pipelines • The role of nitric oxide in host immunity/defense • Strategically working with a partnering organization or spin-off who • Nanotechnology as a delivery system for topical therapeutics focus specifically within certain anti-infective areas • Novel hybrid nitric oxide releasing nanoparticles • Effectively forging a strategic biotech alliance, for optimizing the • Efficacy of nitric oxide releasing nanoparticles against Methicillin development pipeline Resistant Staphylococcus aureus wound and soft tissue infections • Future directions and organisms to be targeted • Successful drug development can shoulder most of the responsibility for developing the next generation of anti-infectives Adam Friedman, MD, Chief Resident, Department of Medicine, • Seeking to build product portfolios within specific anti-infective Division of Dermatology, Albert Einstein College of Medicine therapeutic areas (case study) Nkechi Azie, MD, Senior Medical Director, Astellas Pharma US The Global Growth of Infectious Diseases 11:45 Improving Antibacterial Discovery: A Critical Path 5:15 Emerging Market Countries and Infectious Disease for Minimizing Attrition Due to CV Liabilities Needs • Acute functional cardiovascular toxicity: a special consideration for • Effectively addressing the global threat of new and reemerging infectious diseases antibiotic drug discovery • Inducing international cooperation in identifying, controlling, and • Understanding QT liability and Torsade de Pointes (TdP) during lead preventing these diseases optimization • Examining some basic problems that global campaigns against • Role of hERG inhibition in QT prolongation and Torsade de Points • Beyong hERG assays for predicting TdP risk: Rabbit Ventricular emerging infectious diseases face in applying international law to facilitate international cooperation Wedge assay • Discussing international solutions to emerging infections • Lead optimization for antibacterial programs with respect to acute • Identifying common elements of global emerging-disease control functional cardiovascular toxicity plans Neil D. Pearson, PhD, Director Medicinal Chemistry, • Evaluating alternative international legal strategies to revising the Antibacterial DPU, Infectious Diseases Center of Excellence in International Health Regulations Drug Discovery, GlaxoSmithKline Baoming Jiang, DVM, PhD, Gastroenteritis & Respiratory Viruses Lab Branch, Centers for Disease Control and Prevention 12:30 Networking Lunch 6:00 Chairperson’s Remarks and End of Day 1 3 Register online at or call 1-800-882-8684
  4. 4. Main Conference Day 2 Wednesday, January 27, 2010 7:45 Registration and Coffee Novel Therapeutic Approaches 8:35 Welcome Address and Chairperson’s Opening 1:30 Bacterial Fatty Acid Synthesis as Target for AFN- Remarks 1252, a Novel and Selective-Spectrum Antibiotic for the Treatment of Staphylococcal Infection Update on Antifungals • Unique mechanism of action, selective inhibitor of staphylococcal fatty acid biosynthesis 8:45 Approaches to Novel Antifungal Therapies • Highly potent, optimized to inhibit the staphylococcal FabI enzyme • Finding antifungal targets • Preclinical safety and a selective-spectrum of activity predict minimal • Understanding the role of resistance mechanisms antibiotic treatment related adverse effects • Biologics and other novel approaches • Orally effective in multiple mouse infection models (pneumonia, • Evaluating approaches to modify existing antifungals (polyenes sepsis, thigh and skin abscesses) • Well tolerated in phase 1 clinical studies and azoles) • Introducing novel therapies (peptides, oligonucleotides, and Nachum Kaplan, PhD, Vice President, Microbiology, Affinium monoclonal antibodies (MAbs)) Pharmaceuticals Neil Ryder, PhD, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research 2:15 Target-Based Screening: Discovery of Novel Inhibitors of Bacterial NAD+-Dependent DNA Ligase 9:30 Addressing Serious Fungal Infections & Broad • Discussing in vitro validation of DNA ligase as a target for high Spectrum Clinical Candidates throughput screening • Optimizing potency of enzyme inhibition to achieve antibacterial • Discussing fungi present in the gastrointestinal tract (Candida) or activity in the environment (Aspergillus) • Linking antibacterial activity to inhibition of DNA ligase • Displaying a novel small molecule fungal Hos2 inhibitor that • Achieving in vivo validation of DNA ligase via efficacy in infection enhances the activity and spectrum of current azole treatments model against fungal pathogens when co-administered with azoles Scott Mills, PhD, Principal Scientist, AstraZeneca • Demonstrating how MGCD290 enhances the azole susceptibility of common fungal pathogens such as Candida and Aspergillus 3:00 Networking Break species • Possessing a broad-spectrum inhibitory profile for both class A and Future Anti-Infective Drug Discovery Techniques class C beta-lactamase enzymes, including extended spectrum & Strategies betalactamases (ESBLs) • Overcoming resistance in beta-lactam-resistant organisms such as 3:30 Anti-Infective Drug Discovery through Pseudomonas aeruginosa Jeffrey M. Besterman, PhD, Executive Vice President, R & D Outsourcing and Collaborations • Examining the current paradigm of anti-infective drug discovery and CSO, MethylGene Inc. • Discussing how and why companies are moving compounds ahead when many larger groups have downsized their infectious disease 10:15 Networking Break efforts • Utilizing partners to help overcome significant challenges to public Gram-Positive & Gram-Negative Bacteria healthcare arising from drug resistant bacteria • Progression of anti-infective drug discovery and development 11:00 Multi-Drug Resistant Gram-Negative Bacteria - through the provision of a comprehensive range of highly Real challenges and potential solutions specialized services to the pharmaceutical, biotechnology and • Problem pathogens (drug-resistance in E. coli, K. pneumoniae, P. consumer healthcare sectors • The use and role of the academic collaborator, scientific incubator, aeruginosa and A. baumannii) • Resistance mechanisms in E. coli and K. pneumoniae CRO and CMO – what they need to know to accelerate drug • Resistance mechanisms in P. aeruginosa and A. baumannii development • Current research collaborations for new drug discovery: Big Pharma • Activity of new agents, and compounds in late-stage clincal development, against MDR and Biotech • Activity of experimental compounds in early stage clinical William Weiss, PhD, Director of Pre-Clinical Services, University of North Texas Health Science Center development Malcolm Page, PhD, Head, Biology, Basilea Pharmaceutical International Ltd 4:15 Addressing the Challenge of Fungal Infections: What are our Options? • Discussing fungi such as Aspergillus fumigatus cause a variety of 11:45 Structure-Guided Discovery of serious nosocomial infections in immunocompromised patients (S)-3-(aminomethyl)benzo[c][1,2]oxaborol-1(3H)- • Resulting with their resistance to antibiotics has profound clinical ol hydrochloride (ABX): A First in Class Gram- implications negative Antibacterial • Displaying the three antibiotic classes which are currently in clinical • Examining structure-based design of boron-containing use for fungal infections: amphotericin, echinocandins and azoles antibacterial agents • Examining why all of these classes have efficacy and toxicity • Editing active site of Leucyl tRNA synthetase as a novel drug target drawbacks • In vitro activity of ABX against multi-drug resistant Gram negative • Identifying and discussing approaches towards achieving this include: – Derivatization of echinocandins and azoles bacteria • Discussing oral efficacy of ABX in mouse thigh infection models – Potentiation by modulating resistance mechanisms targeting Vincent Hernandez, Senior Scientist, Medicinal Chemistry, other fungal functions – Importing insights from antiprotozoal and anticancer agents. Anacor Pharmaceuticals Nafsika Georgopapadakou, PhD, Vice President, Research, NovaBay Pharmaceuticals 12:30 Networking Lunch 5:00 End of Summit & Chairperson’s Closing Remarks 4 Register online at or call 1-800-882-8684
  5. 5. Pre-Conference Workshops Monday, January 25, 2010 9:00 am – 12:00 pm (Registration 8:30 am) A Bridging the Scientific and Regulatory Interface For Anti-Infective Drug Development Planning to address both regulatory and scientific issues can speed a company’s time to market on a particular anti-infective drug development How you will benefit: pipeline. Failure to appropriately plan and design studies can delay the • Discover how to avoid failure within phase 3 clinical trials and overall clinical phases of development which can cost millions of dollars and drug development plans potentially end a drug development company’s pipeline prior to product • Keep up to date on the changing regulatory landscape within the anti- launch. Knowing effective regulatory guidelines and a scientific framework infectives arena within which to work is a key goal for companies to speed up their clinical • Benchmark your development pipeline with a number of successful development processes for Anti-Infective drug products. leading clinical drug development organizations • Keep up to speed with drug development leaders buy hearing effective What will be covered: implementation strategies • Overview of regulatory requirements for drug development within the anti-infectives market Your workshop Leader: • Identifying efficient drug development strategies John Powers, MD, Assistant Professor of Medicine, George • Complying with regulatory requirements quickly and efficiently while maintaining safety Washington University School of Medicine and former Lead • Displaying case study examples of effective and ineffective Medical Officer, Antimicrobial Development, US FDA implementation 1:00 pm – 4:00 pm (Registration 12:30 pm) B Phage Therapy within Bacterial Resistance: A Safe and Integrated Approach for the Management of Superbugs The workshop will explore a natural and environmentally friendly How you will benefit: alternative for bacterial resistance: Phage Therapy. Attendees will explore • Phage product development: Learn how to turn a phage into a the various potentials of phages in the diagnosis and management of marketable product bacterial contamination. This session will also focus on how Phage • Uncover technologies and methodologies, large-scale phage production treatment and technologies are continuously being used and developed • Discuss environmental-friendly phage programs to fight bacterial to combat bacterial infection and help assist drug discovery. contamination • Understand when antibiotics are not working anymore and phage What will be covered: therapy is an option • Phage therapy overview • Biosensors • Immunology / Immnotoxicology Speaker opportunities available. • Early work in Eastern countries and recent advances in phage therapy Please contact for more information. • Safety issues: groundbreaking announcement from FDA • Phage therapy as a personalized medicine combining diagnostic and phage therapy Registration Information Pricing Register by Register by Standard December 4, 2009 January 8, 2010 Price Venue: Conference Only (Save $600) (Save $200) Venue is to be announced. $1,199 $1,599 $1,799 Please check the website at All Access (Save $698) (Save $298) (Save $98) $2,199 $2,599 $2,799 for updates and announcements. Workshop Only $549 each $549 each $549 each *All access pass includes conference + all workshops. Details for making payment via EFT or wire transfer: Please note multiple discounts cannot be combined. JPMorgan Chase - Penton Learning Systems LLC dba IQPC: 957-097239 ABA/Routing #: 021000021 A $99 processing charge will be assessed to all registrations not accompanied by Reference: Please include the name of the attendee(s) and the event number: credit card payment at the time of registration. 18354.001 MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC Payment Policy: Payment is due in full at the time of registration and includes * CT residents or people employed in the state of CT must add 6% sales tax. lunches and refreshment. Your registration will not be confirmed until payment is Team Discounts: For information on team discounts, please contact IQPC received and may be subject to cancellation. Customer Service at 1-800-882-8684. Only one discount may be applied per registrant. For IQPC’s Cancellation, Postponement and Substitution Policy, please visit Special Discounts Available: A limited number of discounts are available for the Special Dietary Needs: If you have a dietary restriction, please contact Customer non-profit sector, government organizations and academia. For more information, Service at 1-800-882-8684 to discuss your specific needs. please contact customer service at 1-800-882-8684. ©2010 IQPC. All Rights Reserved. The format, design, content and arrangement of this brochure constitute a trademark of IQPC. Unauthorized reproduction will be actionable under the Lanham Act and common law principles. 5 Register online at or call 1-800-882-8684
  6. 6. International Quality & Productivity Center REGISTRATION CARD 535 5th Avenue, 8th Floor New York, NY 10017 Anti-Infectives YES! Please TM register me for: ❑ Conference Only Summit ❑ All Access* ❑ Conference + 1 workshop ❑ Workshop(s) Only ❑A ❑B See Page 5 for pricing details. Your customer registration code is: When registering, please provide the code above. Name__________________________________ Job Title ________________________ Organization____________________________________________________________ Approving Manager______________________________________________________ Address________________________________________________________________ City__________________________________State______________Zip____________ Phone________________________________Fax_______________________________ E-mail__________________________________________________________________ 5 EASY WAYS TO REGISTER: ❑ Please keep me informed via email about this and other related events. 1 Web: ❑ Check enclosed for $_________ (Payable to IQPC) 2 Call: 1-800-882-8684 ❑ Charge my __Amex __Visa __Mastercard __Diners Club 3 Email: Card #__________________________________Exp. Date___/___ CVM code ______ 4 Fax: 1-646-378-6025 Details for making payment via EFT or wire transfer can be found on preceding page. 5 Mail: IQPC 535 5th Avenue, 8th Floor, ❑ I cannot attend, but please keep me informed of all future events. 18354.001/D/AL New York, NY 10017 Register by December 4th and Save up to $698 Leading Companies Anti-Infectives TM to Present: GlaxoSmithKline Pfizer, Inc. AstraZeneca Summit January 25-27, 2010 • Philadelphia, PA Centers for Disease Control and Prevention Trius Therapeutics Groundbreaking Advances and Key Basilea Pharmaceutical Opinions within Anti-Infective Drug International Ltd Discovery and Development Affinium Pharmaceutiocals Anacor Pharmaceuticals Media Novartis Institute for Partners: Biomedical research Astellas Pharma US Enanta Pharmaceuticals MethylGene, Inc.